Matches in Nanopublications for { <http://bio2rdf.org/drugbank_resource:DB00243_DB01030> ?p ?o ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- drugbank_resource:DB00243_DB01030 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00243_DB01030 label "DDI between Ranolazine and Topotecan - The p-glycoprotein inhibitor, Ranolazine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. [drugbank_resource:DB00243_DB01030]" assertion.
- drugbank_resource:DB00243_DB01030 identifier "drugbank_resource:DB00243_DB01030" assertion.
- drugbank_resource:DB00243_DB01030 title "DDI between Ranolazine and Topotecan - The p-glycoprotein inhibitor, Ranolazine, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided." assertion.